Leveraging Metabolic-Driven Treatment Strategies to Target the Origins of NASH

Join us for an interactive live symposium on the latest findings in NASH clinical management to leverage metabolic origins of NASH as they relate to obesity, T2D, and dyslipidemia. Manal Abdelmalek, MD, MPH, Rohit Loomba, MD, MHSc, and Brent Tetri, MD will provide expert insights on NASH pathophysiology, early therapeutic interventions to improve metabolic processes, and emerging therapeutic targets in late-phase investigations.

Agenda

7:30- Dinner and registration
8:00- 8:05 PM- Opening remarks
Manal Abdelmalek, MD, MPH
8:05- 8:15 PM- Snapshot of NAFLD/NASH epidemiology
Manal Abdelmalek, MD, MPH
8:15- 8:30 PM- NASH origins as a metabolic disease
Brent Tetri, MD
8:30- 8:45 PM- AGA 2021 Clinical Care Pathway for NAFLD
Manal Abdelmalek, MD, MPH, and Rohit Loomba, MD, MHSc
8:45- 9:10 PM- Phase III drugs under investigation for NASH
Manal Abdelmalek, MD, MPH, Rohit Loomba, MD, MHSc, and Brent Tetri, MD
9:10- 9:30 PM- QNA and Closing remarks
Manal Abdelmalek, MD, MPH

Events

Date / Time
Event Details
11/5/2022
7:30 PM

Metabolic-Driven NASH Treatment (November 2022)

Washington, DC
Marriott Marquis Washington, DC Details

Faculty

Program Director
Manal Abdelmalek, MD, MPH

Faculty
Rohit Loomba, MD

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Faculty
Brent A. Tetri, MD

Professor of Internal Medicine
Director,
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St Louis, Missouri

Goal Statement
The goal of this activity is to improve clinical knowledge and competency among hepatologists, gastroenterologists, hepatology/gastroenterology advanced practice providers, and other healthcare professionals interested in advances in treating NASH.

Target Audience
This activity is intended for gastroenterology healthcare professionals, including physicians, nurses, nurse practitioners, and physician associates/physician assistants, and other healthcare professionals who care for patients with NAFLD/NASH.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Detail the pathophysiology shared by obesity, type 2 diabetes, and dyslipidemia that contributes to the genesis of NAFLD
  • Summarize key recommendations from the latest clinical care guidelines for NASH regarding early therapeutic interventions aimed at improving metabolic processes for patients with NAFLD/NASH
  • Compare the efficacy and safety outcomes for NASH drugs in late-phase investigations and potential implications in NASH management

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for maximum of 1.5 hours of AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.